Stock comparison
McKesson
Royalty Pharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MCK
McKesson
Market cap
$92.09B
Sector
Healthcare
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
Overall winner
Royalty Pharma RPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MCK | RPRX | Winner |
|---|---|---|---|
| Warren Buffett | 63C | 66C | RPRX |
| Benjamin Graham | 51C | 84A | RPRX |
| Philip Fisher | 47D | 65C | RPRX |
| Peter Lynch | 48D | 60C | RPRX |
| Joel Greenblatt | 50C | 40D | MCK |
| Charlie Munger | 42D | 68D | RPRX |
| Terry Smith | 53C | 58D | RPRX |
Side-by-side metrics
| Metric | MCK | RPRX |
|---|---|---|
| Market cap | $92.09B | $23.44B |
| P/E (TTM) | 19.5x | 27.6x |
| EV/EBIT | 14.9x | 19.9x |
| ROIC (TTM) | 31.07% | 8.43% |
| Gross margin | 3.61% | 99.95% |
| Net margin | 1.18% | 33.91% |
| Revenue CAGR 5y | 11.19% | 0.96% |
| EPS CAGR 5y | 51.54% | 11.83% |
| Debt / Equity | - | 1.3x |
| Dividend yield | 0.42% | 1.72% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MCK leads on
- Debt / Equity-vs 1.3x+133%
- Revenue CAGR 5y11.19%vs 0.96%+91%
- EPS CAGR 5y51.54%vs 11.83%+77%
- Market cap$92.09Bvs $23.44B+75%
RPRX leads on
- Net margin33.91%vs 1.18%+97%
- Gross margin99.95%vs 3.61%+96%
- Dividend yield1.72%vs 0.42%+76%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.